NL-OMON44525已完成不适用
Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients with Active Refractory Crohn*s Disease - SPM-007
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Male or female subjects aged 18-75 years, inclusive
- •-Written informed consent prior to any of the screening procedures
- •-Diagnosis of Crohn's disease for more than 4 months prior to Week -4 Visit, with small bowel and/or colonic involvement
- •-Current evidence of moderately-to-severely active disease defined by a Week -4 Visit Crohn's Disease Activity Index (CDAI) score of 220 to 450,
- •-Simple Endoscopic Score for Crohn*s Disease evaluation at baseline showing presence of a minimal ulcer score of 2 or 3 in at least 1 segment
- •-Levels of fecal calprotectin greater than or equal to 200 microgram/gram feces at Week -4 Visit
- •-History of inadequate response and/or intolerance or adverse events to one or more TNF-alpha inhibitors (e.g., infliximab, adalimumab, or certolizumab pegol) or vedolizumab.
- •-Female subjects of child-bearing potential are eligible if not pregnant, not planning to become pregnant during the course of the study, and committed to use of contraceptive methods with a failure rate of less than 1 percent per year
排除标准
- •Patients who meet any of the following criteria are not to be enrolled in this study:
- •-Celiac disease
- •-Diagnosis of ulcerative or indeterminate colitis
- •-Enterocutaneous, abdominal or pelvic fistulae with abscesses, or fistulae likely to require surgery during the course of the study period
- •-Bowel surgery, other than appendectomy, within 12 weeks prior to Week -4 Visit and/or has planned surgery or deemed likely to need surgery for Crohn's disease during the study period
- •-Extensive colonic resection, subtotal or total colectomy
- •-Presence of ileostomies, colostomies or rectal pouches
- •-Fixed symptomatic stenoses of small bowel or colon
- •-History of more than 3 small bowel resections or diagnosis of short bowel syndrome
- •-Use of prohibited medications inside the specified washout period (prior to Week -4 Visit), and throughout the study.
- •Prohibited medications include the following:
- •TNF antagonists and vedolizumab may continue throughout the study, but treatments should have been given at a stable dose for at least 6 months prior to the screening date and should be maintained at this level throughout the study.
- •Use of natalizumab within 8 weeks
- •Use of glucocorticoids at doses greater than 10 mg prednisone orally QD, or an equivalent dose of other oral or parenteral glucocorticoids within 4 weeks
- •Use of cyclosporine, tacrolimus, sirolimus or mycophenolate mofetil within 4 weeks
- •Use of intravenous antibiotics for Crohn's disease within 4 weeks
- •Use of parenteral, tube or enteral feeding, or elemental diet within 2 weeks
- •Rectal Treatment: Use of 5-aminosalicylates or corticosteroid enemas or suppositories within 2 weeks
- •Azathioprine, 6-mercaptopurine and methotrexate can be continued throughout the trial. These medications must have been used for >12 weeks, at stable dose for at least 3 weeks prior to the Week -4 Visit.
- •-Leukocytopheresis or granulocytopheresis within 2 weeks prior to Week -4 Visit
- •-Positive immunoassay for Clostridium difficile at Week -4 Visit
- •-Known HIV infection
- •-Known active in infection with HBV or HCV
- •-Current evidence of, or has been treated for a malignancy within the past five years (other than localized basal cell or squamous cell skin cancer, cervical dysplasia, or any cancer which has been fully staged as in situ and has been fully resected)
- •-History of evidence of adenomatous colonic polyps that have not been removed.
- •-Use of any investigational product within 30 days prior to Week -4 Visit for small molecules, or 8 weeks prior for monoclonal antibodies
- •-Significant psychiatric disease or substance abuse
- •-History of unilateral or bilateral vagotomy
- •-History of recurrent vaso-vagal syncope episodes
- •-Known obstructive sleep apnea
- •-Known history of cardiac rhythm disturbances, atrio-ventricular block of greater than first degree, or cardiac conduction pathway abnormalities other than isolated right bundle branch block or isolated left anterior fascicle block. Evaluation by a cardiologist is required if the family history, patient history, or electrocardiogram suggests an abnormal cardiac conduction pathway.
- •-Significant pharyngeal dysfunction or swallowing difficulties
- •-Pre-existing clinically significant vocal cord damage or hoarseness
- •-Previously implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)
研究者
相似试验
已完成
不适用
on-pharmacological techniques for cognitive improvement in schizophreniaSchizophreniaRBR-69g952niversidade Federal de São Paulo
已完成
不适用
Analysis of efficacy and safety of the stimulation of primary motor cortex with rTMS (TEN-P11) in the intractable neuropathic paiIntractable neuropathic painJPRN-UMIN000020291Osaka University Medical Hospital144
招募中
不适用
Pilot Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid ArthritisNL-OMON35837Setpoint Medical6
招募中
不适用
The effect of tDCS brain stimulation on memory improvement in schizophrenic patientsSchizophreniaIRCT20160528028118N2Tabriz University of Medical Sciences60
进行中（未招募）
3 期
Effect of Transcranial Magnetic stimulation with accelerated skill acquisition program on reach-to-grasp performace in stroke patientsSub-acute stroke patientsStrokeTCTR20230629002Faculty of Physical Therapy, Mahidol University22